MPDL3280A With Chemoradiation for Lung Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

January 26, 2016

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Lung CancerNon-Small Cell Lung Cancer
Interventions
DRUG

MPDL3280A

"1200 mg by vein every 3 weeks up to 1 year after completing consolidation chemotherapy.~Group 1: MPDL3280A given after receiving standard chemotherapy and radiation for 6-7 weeks, followed by a 3-4 week rest period.~Group 2: MPDL3280A given with standard chemotherapy, and radiation therapy for 6-7 weeks followed by a rest period of 3-4 weeks, during which time participants receive 1 dose of MPDL3280A but no chemotherapy or radiation."

DRUG

Carboplatin

AUC 2 by vein once a week on Day 1 during radiation therapy. During consolidation chemotherapy, Carboplatin given at AUC 6 by vein on Days 1 and 22 for 2 cycles.

DRUG

Paclitaxel

50 mg/m2 by vein once a week on Day 1 during radiation therapy. During consolidation chemotherapy, Paclitaxel given at 200 mg/m2 on Days 1 and 22 for 2 cycles.

RADIATION

Radiation Therapy

60-66 Gy in 30-33 fractions administered once-daily on Day 1, 5 days a week, for 6 to 7 weeks.

Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT02525757 - MPDL3280A With Chemoradiation for Lung Cancer | Biotech Hunter | Biotech Hunter